Kairos Pharma, LTD. - 8-K Filing Summary
Business Context and Reporting Period
This Form 8-K reports on the results of the 2026 Annual Meeting of Stockholders held by Kairos Pharma, LTD. on June 29, 2026. The Company is an emerging growth company incorporated in Delaware, with its common stock (Symbol: KAPA) trading on the NYSE American.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting outcomes.
Material Changes and Voting Results
At the Annual Meeting, 13,450,506 shares were voted, representing 62.81% of the 21,411,198 eligible shares. The following proposals were approved:
- Election of Directors: All four nominees (John S. Yu, M.D.; Hyun W. Bae, M.D.; Hansoo Michael Keyoung, M.D., Ph.D.; and Rahul Sighvi, Sci.D., MBA) were elected with zero votes against.
- Ratification of Auditors: Stockholders ratified the appointment of Weinberg & Company, P.A. as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
- Reverse Stock Split Authorization: Stockholders approved an amendment to the Certificate of Incorporation authorizing a reverse stock split with a ratio between 1:3 and 1:250. The specific ratio and timing are at the discretion of the Board of Directors.
- Executive Compensation: The Company's executive compensation was approved on an advisory basis.
- Equity Incentive Plan Amendments: Stockholders approved an increase of 5,000,000 shares available for awards under the 2023 Equity Incentive Plan and an "evergreen" provision for an automatic 5% annual increase in available shares for ten years.
Guidance, Outlook, and Risks
The filing text does not provide specific guidance, outlook, management commentary on financial performance, or a discussion of risks and contingencies beyond the authorization of the reverse stock split, which implies potential liquidity or listing standard concerns.
Key Facts for Investor Verification
- Verify the specific reverse stock split ratio and implementation date once determined by the Board of Directors.
- Confirm the impact of the approved equity plan amendments on future share dilution.
- Review the definitive proxy statement filed on May 22, 2026, for detailed rationale behind the reverse stock split and executive compensation.
- Monitor the Company's compliance with NYSE American listing standards following the authorization of the reverse split.